A Phase 2, Open-Label Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Aug 2019
Price : $35 *
At a glance
- Drugs Daratumumab (Primary) ; Dexamethasone (Primary) ; Ixazomib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Takeda Oncology
- 01 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2018 Status changed from not yet recruiting to recruiting.
- 01 Jun 2018 Planned initiation date changed from 1 Mar 2018 to 30 Jun 2018.